Delee is currently in the Test the Waters Phase for Title III investments.

Delee

Blood testing platform for early cancer diagnosis & treatment monitoring

Delee

Blood testing platform for early cancer diagnosis & treatment monitoring

Laredo, TX
Health Tech
At Delee, we have created the CytoCatch™️ isolation platform and imaging system. These units enable the performance of a CTC blood-based assay that has the potential of being used for early cancer detection and monitoring the applied treatments’ effectiveness, allowing the optimization of each patient’s therapy throughout the course of the disease.

Terms

Equity
Offering Type
$22M
Valuation
$1.66
Price per Share
$199.20
Min. Reservation
Preferred
Shares Offered
TTW
Offering

Terms

Equity
Offering Type
$22M
Valuation
$1.66
Price per Share
$199.20
Min. Reservation
Preferred
Shares Offered
TTW
Offering

Rewards

Get rewarded for investing more into Delee:

$199+
Investment
TTW Reservation Perks*
Invest during the Test The Waters offering receive 10% Bonus Shares. The reservation perks are in addition to company-specific perks while the campaign is live.

NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED, AND IF SENT IN RESPONSE, WILL NOT BE ACCEPTED. NO OFFER TO BUY THE SECURITIES CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE RECEIVED UNTIL THE OFFERING STATEMENT IS FILED AND ONLY THROUGH AN INTERMEDIARY’S PLATFORM. AN INDICATION OF INTEREST INVOLVES NO OBLIGATION OR COMMITMENT OF ANY KIND.  "RESERVING" SECURITIES IS SIMPLY AN INDICATION OF INTEREST.


Reasons to Invest

1

Delee uses a blood-based assay enabled by two independent devices created to effectively isolate and analyze circulating tumor cells (CTCs). Our technology is being successfully tested for its use in prostate and breast cancer.

2

We are backed by Y Combinator and StartX and have raised over $2.4 million USD in funding, and our pre-orders are already potentially worth over $2.5 million. 

3

Our fully functional technology was built by an experienced team of specialists in the fields of molecular biology, electronics, artificial intelligence, clinical oncology, and design and manufacture.

*Delee is in the prototype phase. Delee is not currently available on the market.

The information presented during this Testing the Waters (“TTW”) campaign is preliminary and may change. Although any indications of interest are non-binding, a TTW campaign enables the issuer to test and determine the viability of its prospective offering without incurring significant expenses. No offer to buy the security can be accepted until a formal offering is conducted. These TTW communications will be included in the formal offering when filed, so that investors can receive all the information and disclosures that were disseminated.

Offering Summary


Company

:

DELEE Corp.

Corporate Address

:

1211 San Dario Ave #2068, Laredo, TX 78040

Offering Minimum

:

$9,999.84

Offering Maximum

:

$4,999,998.02

Minimum Investment Amount

(per investor)

:

$199.20











Terms


Offering Type

:

Equity

Security Name

:

Series V Preferred Stock

Minimum Number of Shares Offered

:

6,024

Maximum Number of Shares Offered

:

3,012,047

Price per Share

:

$1.66

Pre-Money Valuation

:

$22,040,057.38











Early Bird

Friends and Family - First 72 hours | 15% bonus shares

Super Early Bird - Next 7 days | 10% bonus

Early Bird Bonus - Next 10 days | 5% bonus shares

TTW Reservation Perks*

TTW Perk: Invest during the Test The Waters offering receive 10% Bonus Shares. The reservation perks are in addition to company-specific perks while the campaign is live.

*Note these perks do stack with the other live offering perks. The Company may provide additional perks based on different criteria if and when the offering campaign becomes live.

The Company will not incur any irregular use of proceeds.


Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
USD
USD
Cash And Cash Equivalents
USD
USD
Accounts Receivable
USD
USD
Short Term Debt
USD
USD
Long Term Debt
USD
USD
Revenues And Sales
USD
USD
Costs Of Goods Sold
USD
USD
Taxes Paid
USD
USD
Net Income
USD
USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

The final version of the CytoCatch™️ imaging system is finally here 🙌

12 days ago

We hope that you and yours are well and safe 😄

 

A few weeks ago we announced that the final version of the CytoCatch™️ isolation platform had been completed. Today we have another exciting announcement, the final version of the CytoCatch™️ imaging system is finally completed 🥳

 

microscope 1 gif


After concluding our previous crowdfunding campaign we found ourselves in a very difficult situation, with the pandemic raging we had to coordinate with every member of our team to efficiently work both from our homes and lab. To be able to share this news with you fills every member of the team with a tremendous amount of joy. 

 

The CytoCatch™️ imaging system is the most complex unit that constitutes our technology. This system was specially designed to acquire high-resolution micrographs of the CTCs that were previously captured by our isolation platform. It possesses special routines and machine learning algorithms that analyze the captured cells based on their morphology and the expression of specific markers. All these processes, ranging from image acquisition to image analysis, are fully automated, which increases the reliability and reproducibility of the assay by preventing human error.

 

 

microscope 2 gif c


Our StartEngine campaign launching soon, remember that you can still reserve your investment and receive 10% bonus shares

 

We are deeply grateful for your unwavering support, we know that none of these amazing achievements would have been possible without each and every one of you. From the bottom of our hearts, thank you!

 

Sincerely, 

 

Delee Team 💙

Delee has started the analytical validation of the CytoCatch™ isolation platform.

20 days ago

Hello everyone! 


We hope you’re doing well 😄.


We would like to share with you that last week we began the analytical validation of the final version of the CytoCatch™ isolation platform, one of the two devices that constitute our technology and makes it possible to isolate CTCs from other blood components. 



This validation is fundamental for any medical or scientific device built to measure an analyte (the constituent of the sample to be analyzed, in our case the CTCs). The tests carried out during this validation are designed to ensure that our platform’s performance is optimal and the results obtained are reproducible. Here, our device will be extensively tested to assess key parameters, such as capture efficiency, purity, sensitivity, working range, precision, and accuracy. This has to be made before the device’s clinical validation, where a clinical study is going to be conducted in order to collect clinical data. 


Even though this is just the beginning, and this validation will last for several months, we are thrilled because the first tests carried out yielded very positive results. Our device consistently had over 94% capture efficiency when processing blood samples of 7.5 mL spiked with 100 cancer cells. This means that our device was able to capture over 94 of these cells in every run performed, which is in line or even higher than our competitors’ yield 😎.



We are deeply thankful to all the people who already reserved their investment 🤗. At the moment, we are still in the Test The Waters (TTW) stage, in which you can reserve your investment without committing until the campaign goes officially live. If you reserve during the TTW stage you will receive 10% bonus shares when you confirm the investment.


Once again, thank you for all your support!


Sincerely, 


Delee Team 💙

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
Please sign in to post a comment.
Please use Updates for communications.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}